The ongoing issues surrounding certain Oculentis intraocular lenses (IOLs) continue to generate significant legal and professional concern within ophthalmology. While the original problems stemmed from the manufacture of the lenses themselves, an increasing number of claims are now being directed towards ophthalmic surgeons, clinics, and healthcare providers involved in supplying and implanting the affected products.
Background to the Oculentis Lens Issue
Oculentis manufactured a range of premium intraocular lenses used in cataract and refractive lens exchange procedures. Over time, concerns emerged regarding the opacification or calcification of certain lens models, resulting in clouding of the lens and a deterioration in patients’ vision. Field Safety Notices and product recalls were issued in relation to lenses manufactured during specific periods after reports of increased rates of postoperative opacification. Investigations suggested that the problem was linked to the manufacturing process rather than surgical implantation.
Many affected patients experienced visual deterioration several years after surgery and, in some cases, required complex lens exchange procedures to restore vision. Approximately 800 patients were reported to have experienced lens opacification, although the number of implanted lenses was significantly higher.
The Manufacturer’s Bankruptcy
A significant development in these cases was the bankruptcy of Oculentis in 2021. As a result, many patients seeking compensation found that pursuing claims directly against the manufacturer became substantially more difficult. Legal proceedings against the company were effectively halted, leaving claimants to consider alternative defendants.
This has resulted in increased scrutiny of clinics, hospitals, and surgeons involved in the supply and implantation of the lenses.
Why Are Surgeons Being Targeted?
Traditionally, product defect claims would focus primarily on the manufacturer. However, under various product liability and consumer protection frameworks, liability may extend beyond the manufacturer to those involved in the supply chain.
A crucial distinction must be made between the role of the implanting surgeon and the role of the supplier of the lens.
In the traditional private practice model, the intraocular lens is usually purchased by, supplied by, and charged to the patient by the private hospital or clinic, such as Nuffield Health, Spire Healthcare, or a similar provider. In those circumstances, the hospital or clinic is generally the supplier of the product. If the lens later proves defective and the manufacturer is insolvent or has ceased trading, product liability claims are likely to be directed towards the organisation that supplied the lens to the patient rather than the surgeon who implanted it.
The position can be very different where the ophthalmic surgeon personally purchases the lenses from the manufacturer and then sells them directly to patients as part of their surgical package. Historically this has been relatively unusual. However, as surgical fees and practice margins have come under increasing pressure, some surgeons have chosen to purchase premium intraocular lenses themselves and resell them to patients, sometimes generating a significant additional profit on the lens component of the procedure.
In these circumstances, the surgeon may move beyond the role of clinician and become the supplier of the product. If the lens subsequently proves defective and the manufacturer is no longer available to meet claims, the surgeon may find themselves exposed to product liability allegations because they personally supplied and sold the lens to the patient.
This distinction is critical. Merely implanting a defective lens does not automatically make a surgeon liable for the defect. However, personally supplying and charging for the lens may place the surgeon directly within the product supply chain, creating potential exposure that would otherwise have rested with the hospital or clinic.
The Growing Risk for Ophthalmic Surgeons
The increase in Oculentis-related litigation highlights an important risk for ophthalmic surgeons. Many surgeons understandably view themselves as clinicians selecting products manufactured by reputable medical device companies. However, where surgeons choose to purchase and resell lenses directly to patients, they may inadvertently assume responsibilities that extend beyond clinical care.
Even where there is no criticism whatsoever of the surgical technique, patient selection, consent process, or postoperative care, a surgeon who acted as the supplier of the lens may still find themselves involved in lengthy and costly legal proceedings if the device subsequently fails.
By contrast, where the lens was supplied and charged for by the hospital or clinic, product liability arguments are far more likely to focus on that organisation’s role as supplier, particularly where the manufacturer is no longer available to compensate affected patients.
Defending such claims can be particularly challenging when the manufacturer is insolvent and unable to provide evidence, indemnity, or financial contribution towards settlements.
Lessons for the Profession
The Oculentis experience serves as an important reminder that ophthalmic surgeons face risks extending beyond allegations of clinical negligence. Product liability exposures should be considered alongside traditional malpractice risks.
Perhaps the most important practical lesson is that surgeons should carefully consider whether they wish to become involved in the supply of intraocular lenses at all. While purchasing lenses directly from manufacturers and reselling them to patients may create an additional revenue stream, it can also bring with it product liability exposure that would otherwise sit with the hospital or clinic acting as supplier.
Practices should ensure that:
- Appropriate supplier agreements are in place.
- Product traceability records are maintained.
- Professional indemnity arrangements provide adequate protection for product-related claims.
- Patients are appropriately informed about the benefits and risks of implanted devices.
- Robust due diligence is undertaken when selecting premium IOL manufacturers and suppliers.
- Surgeons fully understand the legal implications of personally supplying medical devices to patients.
Looking Ahead
The Oculentis litigation demonstrates how responsibility for a defective medical device can extend beyond the original manufacturer. As manufacturers face financial pressures and, in some cases, cease trading, claimants are increasingly looking elsewhere for compensation.
A further development that surgeons should be aware of is the increasing scrutiny being applied by professional indemnity insurers to arrangements involving the supply of intraocular lenses. Some underwriters are now specifically asking whether ophthalmic surgeons personally purchase and supply lenses to patients and, where they do, are applying additional premiums or tariffs to indemnity costs to reflect the potential exposure to product liability claims. This reflects a growing recognition within the insurance market that surgeons who act as suppliers of medical devices may face risks that extend beyond traditional clinical negligence claims. As a result, surgeons considering direct lens supply arrangements should carefully assess not only the legal implications but also the potential impact on their professional indemnity costs.
For ophthalmic surgeons, the key lesson is clear. If the intraocular lens is supplied and charged for by the hospital or clinic, product liability issues will usually be directed towards that supplier if the manufacturer cannot meet the claim. However, where the surgeon has personally purchased, supplied and sold the lens to the patient, they may find themselves standing in the shoes of the supplier and facing claims that would otherwise have been directed elsewhere.
Understanding exactly where one sits in the supply chain, and ensuring that appropriate legal and insurance protections are in place, has never been more important.
This article is intended for general information only and does not constitute legal advice. Specific liability will depend on the facts of each case and the applicable law in the relevant jurisdiction.
